ATE304855T1 - Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen - Google Patents
Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungenInfo
- Publication number
- ATE304855T1 ATE304855T1 AT01112981T AT01112981T ATE304855T1 AT E304855 T1 ATE304855 T1 AT E304855T1 AT 01112981 T AT01112981 T AT 01112981T AT 01112981 T AT01112981 T AT 01112981T AT E304855 T1 ATE304855 T1 AT E304855T1
- Authority
- AT
- Austria
- Prior art keywords
- mental disorders
- olnzapine
- cerebrovascular diseases
- disorders caused
- treat mental
- Prior art date
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 1
- 229960005017 olanzapine Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP00319195A JP3274579B2 (ja) | 1995-01-12 | 1995-01-12 | 脳血管障害に伴う精神症候治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE304855T1 true ATE304855T1 (de) | 2005-10-15 |
Family
ID=11550523
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01112981T ATE304855T1 (de) | 1995-01-12 | 1996-01-11 | Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen |
AT96100360T ATE210984T1 (de) | 1995-01-12 | 1996-01-11 | Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96100360T ATE210984T1 (de) | 1995-01-12 | 1996-01-11 | Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1181935B1 (de) |
JP (1) | JP3274579B2 (de) |
KR (1) | KR100397525B1 (de) |
CN (1) | CN1088359C (de) |
AT (2) | ATE304855T1 (de) |
CA (1) | CA2167004C (de) |
DE (2) | DE69618047T2 (de) |
DK (1) | DK0730865T3 (de) |
ES (2) | ES2249352T3 (de) |
PT (1) | PT730865E (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA57727C2 (uk) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
EP0906104A4 (de) * | 1996-03-25 | 2003-12-10 | Lilly Co Eli | Schmerzbehandlungsverfahren |
EP1155696B1 (de) * | 1997-04-15 | 2004-03-03 | Eli Lilly And Company | Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion |
US5902807A (en) * | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
WO1999032108A1 (en) * | 1997-12-19 | 1999-07-01 | Akzo Nobel N.V. | Org-5222 in the treatment of depression |
UA70334C2 (en) * | 1998-10-06 | 2004-10-15 | Janssen Pharmaceutica N V Jans | BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS |
JP2004262812A (ja) * | 2003-02-28 | 2004-09-24 | Rohto Pharmaceut Co Ltd | 眼圧低下剤 |
BRPI0410378A (pt) * | 2003-05-16 | 2006-06-13 | Pfizer Prod Inc | tratamento de distúrbios psicóticos e depressivos |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
AU2007255724B2 (en) * | 2006-06-09 | 2012-05-10 | Dainippon Sumitomo Pharma Co., Ltd. | Novel tape preparation |
CA2687979C (en) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
EP3558276A1 (de) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermales therapeutisches system mit asenapin und polysiloxan oder polyisobutylen |
JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
MX2020014286A (es) | 2018-06-20 | 2021-03-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
WO2020145359A1 (ja) * | 2019-01-09 | 2020-07-16 | 山田 健一 | 脳血管障害および認知症の治療のための医薬組成物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
NO154582C (no) * | 1978-10-20 | 1986-11-05 | Ferrosan Ab | Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider. |
JPH0625181B2 (ja) * | 1985-03-27 | 1994-04-06 | 住友製薬株式会社 | 新規なイミド誘導体 |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
US4636563A (en) * | 1985-09-16 | 1987-01-13 | American Home Products Corporation | Antipsychotic γ-carbolines |
MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
JPH0747574B2 (ja) * | 1989-03-03 | 1995-05-24 | 大日本製薬株式会社 | ピリジン誘導体及びそれを有効成分とする向精神剤 |
ES2076253T3 (es) * | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
NZ236501A (en) * | 1989-12-21 | 1992-12-23 | Merrell Dow Pharma | Piperidine derivatives and antithrombotic compositions |
GB9008850D0 (en) * | 1990-04-19 | 1990-06-13 | Janssen Pharmaceutica Nv | Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
JP3063263B2 (ja) * | 1991-07-31 | 2000-07-12 | スズキ株式会社 | ミッションケース構造 |
HUT70031A (en) * | 1992-11-30 | 1995-09-28 | Sankyo Co | Alfa, omega-diarylalkane derivatives, their preparation and pharmaceutical compositions containing them |
GB9302622D0 (en) * | 1993-02-10 | 1993-03-24 | Wellcome Found | Heteroaromatic compounds |
JP3007257B2 (ja) * | 1994-03-03 | 2000-02-07 | ローム株式会社 | サーマルプリントヘッド |
CA2144669A1 (en) * | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
EP0828494B1 (de) * | 1995-05-30 | 2002-07-17 | Eli Lilly And Company | Verfahren zur behandlung von wahrnehmungsstörungen |
-
1995
- 1995-01-12 JP JP00319195A patent/JP3274579B2/ja not_active Expired - Fee Related
-
1996
- 1996-01-11 EP EP01112981A patent/EP1181935B1/de not_active Expired - Lifetime
- 1996-01-11 ES ES01112981T patent/ES2249352T3/es not_active Expired - Lifetime
- 1996-01-11 DE DE69618047T patent/DE69618047T2/de not_active Expired - Lifetime
- 1996-01-11 DK DK96100360T patent/DK0730865T3/da active
- 1996-01-11 AT AT01112981T patent/ATE304855T1/de not_active IP Right Cessation
- 1996-01-11 ES ES96100360T patent/ES2170176T3/es not_active Expired - Lifetime
- 1996-01-11 PT PT96100360T patent/PT730865E/pt unknown
- 1996-01-11 EP EP96100360A patent/EP0730865B1/de not_active Expired - Lifetime
- 1996-01-11 DE DE69635213T patent/DE69635213T2/de not_active Expired - Lifetime
- 1996-01-11 KR KR1019960000461A patent/KR100397525B1/ko not_active IP Right Cessation
- 1996-01-11 CA CA002167004A patent/CA2167004C/en not_active Expired - Fee Related
- 1996-01-11 AT AT96100360T patent/ATE210984T1/de active
- 1996-01-12 CN CN96101615A patent/CN1088359C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1088359C (zh) | 2002-07-31 |
KR100397525B1 (ko) | 2003-11-20 |
DE69635213D1 (de) | 2006-02-02 |
CA2167004A1 (en) | 1996-07-13 |
DE69618047D1 (de) | 2002-01-31 |
DE69635213T2 (de) | 2006-11-23 |
DK0730865T3 (da) | 2002-04-02 |
EP1181935A3 (de) | 2002-03-06 |
EP1181935A2 (de) | 2002-02-27 |
ES2249352T3 (es) | 2006-04-01 |
KR960028905A (ko) | 1996-08-17 |
EP0730865B1 (de) | 2001-12-19 |
EP0730865A1 (de) | 1996-09-11 |
DE69618047T2 (de) | 2002-06-20 |
PT730865E (pt) | 2002-04-29 |
CA2167004C (en) | 2006-09-12 |
JP3274579B2 (ja) | 2002-04-15 |
ATE210984T1 (de) | 2002-01-15 |
EP1181935B1 (de) | 2005-09-21 |
CN1142945A (zh) | 1997-02-19 |
JPH08193033A (ja) | 1996-07-30 |
ES2170176T3 (es) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE304855T1 (de) | Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen | |
ATE324908T1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
DE69535498D1 (de) | Verfahren zur behandlung vaskulärer kopfschmerzen | |
DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE69328474D1 (de) | Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose | |
ATE194593T1 (de) | 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten | |
ATE255896T1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
DE69411424D1 (de) | Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole | |
DE69616376T2 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
DE69530933D1 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
DE69534908D1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
ATE329588T1 (de) | Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen | |
ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
ATE125704T1 (de) | Behandlung neurodegenerativer erkrankungen. | |
ATE222491T1 (de) | Melatonin-derivate zur verwendung in der behandlung von schlafstörungen | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
ATE431735T1 (de) | Fusionierte cycloalkyl amid- und carbonsäure- derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie | |
DE69623767T2 (de) | Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus | |
DE59609219D1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen | |
ATE225181T1 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen | |
ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
DE69915849D1 (de) | Verwendung von gnrh analogen zur behandlung von schizophrenie | |
DE69830811D1 (de) | Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis | |
DE69626260D1 (de) | Zusammensetzungen zur Vorbeugung und Behandlung von urogenitalen Störungen, die Wismut enthalten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |